ESTRO 2024 - Abstract Book

S1814

Clinical - Lung

ESTRO 2024

Clinical Variable

Overall Survival HR (mv)

Progression-Free Survival HR (mv)

N (%)*

OMD Pattern

Mixed-pattern

61 (31.6)

Reference

Reference

0.60

(0.35-1.02,

0.58

(0.37-0.91,

Extracranial

74 (38.3)

p=0.058)

p=0.019)

0.55

(0.33-0.92,

0.47

(0.31-0.73,

Intracranial

58 (30.1)

p=0.024)

p=0.001)

OMD Stage

De-novo

141 (73.1)

Reference

Reference

1.21

(0.52-2.82,

0.99

(0.52-1.90,

Induced

18 (9.3)

p=0.661)

p=0.977)

0.99

(0.55-1.77,

0.80

(0.51-1.26,

Repeat

34 (17.6)

p=0.969)

p=0.333)

OMD

Under

Systemic Therapy

Oligorecurrence

122 (63.2)

Reference

Reference

Oligoprogression/ - persistence

0.64

(0.40-1.02,

0.77

(0.54-1.11,

71 (36.8)

p=0.063)

p=0.164)

Number

Of

1.06

(0.88-1.29,

1.03

(0.88-1.21,

Mean (SD)

1.8 (1.2)

Metastases

p=0.533)

p=0.674)

Histology

Adenocarcinoma

149 (77.2)

Reference

Reference

Squamous carcinoma

cell

2.35

(1.30-4.24,

1.04

(0.63-1.72,

28 (14.5)

p=0.005)

p=0.865)

2.12

(1.06-4.21,

1.54

(0.81-2.91,

Other

16 (8.3)

p=0.033)

p=0.187)

ECOG

0

32 (19.6)

Reference

Reference

1.78

(0.97-3.28,

1.45

(0.91-2.33,

1

104 (63.8)

p=0.062)

p=0.121)

2.76

(1.29-5.92,

1.43

(0.77-2.66,

2-3

27 (16.6)

p=0.009)

p=0.259)

Figure 3: Multivariable analysis of clinical variables for OS and PFS. N (%) = absolute number (percentage), *when not Mean (SD). SD = standard deviation. HR = hazard ratio. mv = multivariable analysis. OMD = oligometastatic disease. ECOG = Eastern Cooperative Oncology Group performance status. Upon multivariable analysis, adenocarcinoma histology and a better ECOG at OMD diagnosis were associated with a significantly longer OS, while mixed-pattern OMD was associated with significantly shorter OS. The OMD pattern was the only clinical variable in our analysis that was significantly associated with PFS.

Conclusion:

A significantly shorter OS and PFS were observed in patients with mixed-pattern OMD when compared to those with isolated intracranial or extracranial OMD. While a correlation of OS with histology, ECOG, and OMD pattern could be demonstrated, only the OMD pattern showed an influence on PFS. We postulate that the joint presence of extracranial and intracranial metastases is an adverse prognostic factor in oligometastatic NSCLC patients, compared to either isolated extracranial or intracranial disease. These findings may help to develop more precise prognostic models for patients with OMD.